Adopting the advice of its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention last night recommended the Pfizer-BioNTech vaccine for children aged 12 to 15, paving the way for providers to begin vaccinating them immediately. The Food and Drug administration Monday authorized emergency use of the vaccine in this age group. 

“I encourage parents with questions to talk to your child’s healthcare provider or your family doctor to learn more about the vaccine,” said CDC Director Rochelle Walensky, M.D. “And if your adolescent is behind on routinely recommended vaccines due to the pandemic or for other reasons, now would be a good time to work with your child’s nurse or doctor to make sure they get caught up.”

CDC tomorrow will host a call for clinicians on the recommendations and clinical guidance for using the Pfizer-BioNTech vaccine in this age group. The agency plans to post a recording a few hours after the 2 p.m. ET call for those unable to attend. 
 

FDA previously authorized the vaccine for Americans aged 16 and older.

Related News Articles

Headline
The Health Resources and Services Administration has reimbursed more than 5 million claims to administer COVID-19 vaccine to uninsured individuals, the agency…
Headline
The Centers for Disease Control and Prevention Friday awarded states and other jurisdictions $200 million in supplemental funding from the American Rescue Plan…
Headline
The Department of Health and Human Services today announced a $3 billion investment in antiviral treatments for COVID-19, particularly those administered…
Headline
The Centers for Disease Control and Prevention June 11 updated requirements for health care providers participating in the COVID-19 Vaccination Program to…
Headline
The Food and Drug Administration yesterday authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson &…
Headline
Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of…